ERBB2 and neoplasm: Further analyses on tumor cells suggested that sustained drug release provided by the cMLVs would intensify the antitumor effect of the NKCs, and combined with the CAR‐mediated response in the presence of HER2 or CD19 positive tumor cells, strong tumor toxicity could be expected.